| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
46,276 |
41,206 |
$3.63M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
36,617 |
31,239 |
$3.07M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
24,006 |
21,749 |
$1.83M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
12,086 |
10,976 |
$986K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
8,086 |
6,942 |
$557K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,000 |
2,547 |
$470K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,957 |
8,487 |
$324K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,615 |
5,983 |
$324K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,994 |
4,760 |
$319K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,718 |
4,326 |
$193K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,899 |
2,281 |
$193K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,232 |
1,033 |
$151K |
| 80053 |
Comprehensive metabolic panel |
26,645 |
21,374 |
$146K |
| 36415 |
Collection of venous blood by venipuncture |
31,030 |
25,189 |
$142K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,666 |
6,258 |
$139K |
| G0378 |
Hospital observation service, per hour |
13,522 |
5,057 |
$125K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
879 |
733 |
$121K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,140 |
2,229 |
$100K |
| 99215 |
Prolong outpt/office vis |
1,812 |
1,112 |
$98K |
| 82962 |
|
8,833 |
3,881 |
$96K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
4,115 |
3,447 |
$88K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
2,070 |
1,775 |
$87K |
| 71046 |
Radiologic examination, chest; 2 views |
6,863 |
6,023 |
$78K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,766 |
2,036 |
$77K |
| 29580 |
|
1,584 |
349 |
$76K |
| 81025 |
|
13,963 |
12,457 |
$73K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
5,050 |
2,628 |
$71K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
13,200 |
9,718 |
$64K |
| 87631 |
|
1,022 |
942 |
$58K |
| 84702 |
|
11,528 |
9,693 |
$55K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,441 |
2,406 |
$52K |
| 73130 |
|
1,247 |
1,069 |
$50K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
480 |
377 |
$50K |
| 87088 |
|
6,634 |
5,638 |
$49K |
| 29581 |
|
600 |
154 |
$44K |
| 85027 |
|
4,733 |
3,655 |
$44K |
| 73562 |
|
1,728 |
1,515 |
$43K |
| 73630 |
|
1,608 |
1,416 |
$43K |
| 73610 |
|
1,211 |
1,074 |
$43K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
89 |
88 |
$42K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,064 |
2,006 |
$40K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
14,256 |
11,345 |
$38K |
| 86900 |
|
1,596 |
1,292 |
$35K |
| 71045 |
Radiologic examination, chest; single view |
9,150 |
7,414 |
$33K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
6,614 |
6,051 |
$32K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
36,210 |
27,994 |
$32K |
| 87486 |
|
1,033 |
933 |
$30K |
| 84484 |
|
11,415 |
6,787 |
$30K |
| 87186 |
|
2,195 |
1,674 |
$23K |
| 81001 |
|
21,248 |
18,280 |
$22K |
| 81003 |
|
7,348 |
6,289 |
$22K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
684 |
617 |
$22K |
| 73110 |
|
597 |
535 |
$20K |
| 73030 |
|
1,000 |
812 |
$19K |
| 86850 |
|
976 |
800 |
$17K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,059 |
958 |
$15K |
| 83880 |
|
894 |
682 |
$14K |
| J2704 |
Injection, propofol, 10 mg |
2,431 |
1,940 |
$14K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
8,825 |
6,721 |
$13K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,508 |
6,165 |
$13K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
14,572 |
12,117 |
$13K |
| 85610 |
|
5,510 |
4,099 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,948 |
1,482 |
$12K |
| 10060 |
|
777 |
691 |
$11K |
| 85730 |
|
3,095 |
2,364 |
$10K |
| 83690 |
|
9,105 |
7,639 |
$10K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
14 |
14 |
$9K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,637 |
1,307 |
$9K |
| 73140 |
|
204 |
184 |
$9K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
87 |
85 |
$9K |
| 76801 |
|
1,245 |
1,005 |
$8K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
141 |
113 |
$8K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,958 |
1,260 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,806 |
7,700 |
$7K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,333 |
1,913 |
$7K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
547 |
449 |
$7K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
57 |
40 |
$6K |
| 93976 |
|
213 |
196 |
$6K |
| 87581 |
|
1,034 |
933 |
$5K |
| 87070 |
|
797 |
619 |
$5K |
| 87077 |
|
2,428 |
1,788 |
$5K |
| 80061 |
Lipid panel |
2,184 |
1,806 |
$5K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
116 |
82 |
$4K |
| 87040 |
|
1,418 |
675 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
4,597 |
2,863 |
$4K |
| 93971 |
|
388 |
325 |
$4K |
| 94010 |
|
1,564 |
986 |
$4K |
| 85379 |
|
1,534 |
1,281 |
$4K |
| 94760 |
|
407 |
329 |
$3K |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
4,170 |
2,922 |
$3K |
| 74018 |
|
408 |
329 |
$3K |
| 87210 |
|
5,297 |
4,713 |
$3K |
| 76830 |
Ultrasound, transvaginal |
405 |
361 |
$3K |
| 12001 |
|
233 |
208 |
$3K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
2,702 |
1,183 |
$3K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,308 |
969 |
$3K |
| 83735 |
|
2,091 |
1,484 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
32 |
13 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,397 |
2,046 |
$2K |
| 86901 |
|
1,584 |
1,278 |
$2K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
991 |
800 |
$2K |
| 90715 |
|
1,172 |
939 |
$2K |
| 93970 |
|
35 |
28 |
$2K |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
85 |
53 |
$2K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
2,821 |
2,196 |
$2K |
| 17250 |
|
160 |
89 |
$2K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
351 |
298 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
611 |
396 |
$2K |
| 87205 |
|
814 |
634 |
$2K |
| 72100 |
|
270 |
242 |
$2K |
| 80076 |
|
685 |
579 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,955 |
2,076 |
$1K |
| 94668 |
|
117 |
39 |
$1K |
| 88304 |
|
99 |
85 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,835 |
1,504 |
$1K |
| 12011 |
|
105 |
95 |
$1K |
| 73080 |
|
62 |
52 |
$1K |
| 83605 |
|
1,271 |
871 |
$1K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
909 |
575 |
$1K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
1,218 |
385 |
$1K |
| 74021 |
|
170 |
148 |
$1K |
| 94667 |
|
64 |
47 |
$1K |
| 86403 |
|
93 |
83 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
266 |
178 |
$1K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,929 |
1,827 |
$1K |
| 29125 |
|
496 |
451 |
$958.56 |
| 82550 |
|
1,047 |
769 |
$922.47 |
| 70486 |
|
14 |
12 |
$891.36 |
| 29530 |
|
55 |
53 |
$888.01 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
958 |
839 |
$852.08 |
| 73590 |
|
15 |
13 |
$733.70 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
22 |
14 |
$722.16 |
| 73502 |
|
159 |
137 |
$682.49 |
| 86140 |
|
255 |
196 |
$651.33 |
| 29130 |
|
214 |
199 |
$644.60 |
| 85651 |
|
444 |
318 |
$626.83 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
917 |
577 |
$626.04 |
| 74019 |
|
170 |
158 |
$609.77 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
234 |
177 |
$589.73 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,668 |
4,278 |
$449.70 |
| J2060 |
Injection, lorazepam, 2 mg |
576 |
383 |
$446.74 |
| 94762 |
|
36 |
33 |
$410.32 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,415 |
1,134 |
$406.78 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
135 |
109 |
$389.57 |
| 87184 |
|
43 |
36 |
$226.30 |
| 84439 |
|
198 |
163 |
$210.80 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
77 |
65 |
$206.68 |
| 88342 |
|
140 |
127 |
$192.64 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
57 |
13 |
$191.08 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
163 |
147 |
$182.30 |
| 87075 |
|
114 |
79 |
$173.20 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
261 |
246 |
$86.96 |
| 82728 |
|
34 |
25 |
$78.86 |
| 96376 |
|
168 |
148 |
$78.46 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
27 |
15 |
$60.00 |
| 84100 |
|
92 |
65 |
$59.26 |
| 3044F |
|
784 |
469 |
$40.00 |
| 72040 |
|
56 |
50 |
$38.61 |
| 87081 |
|
105 |
105 |
$23.41 |
| 99406 |
|
16 |
12 |
$21.71 |
| 84145 |
|
20 |
12 |
$16.14 |
| 83540 |
|
28 |
25 |
$7.81 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
30 |
13 |
$7.59 |
| 3725F |
|
9,697 |
5,616 |
$0.00 |
| 1160F |
|
198 |
188 |
$0.00 |
| 3078F |
|
2,067 |
1,185 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
477 |
464 |
$0.00 |
| 36600 |
|
15 |
12 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
18 |
15 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
34 |
30 |
$0.00 |
| 82570 |
|
60 |
54 |
$0.00 |
| 82272 |
|
15 |
12 |
$0.00 |
| 1159F |
|
213 |
202 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
12 |
12 |
$0.00 |
| 00731 |
|
91 |
91 |
$0.00 |
| 29515 |
|
41 |
39 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
158 |
68 |
$0.00 |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
22 |
14 |
$0.00 |
| 99080 |
|
30 |
27 |
$0.00 |
| 99499 |
|
18 |
17 |
$0.00 |
| 3008F |
|
5,795 |
3,422 |
$0.00 |
| 1126F |
|
3,676 |
2,054 |
$0.00 |
| 3351F |
|
6,493 |
3,769 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
7,817 |
4,463 |
$0.00 |
| 3074F |
|
1,085 |
619 |
$0.00 |
| 1170F |
|
495 |
257 |
$0.00 |
| 29540 |
|
55 |
52 |
$0.00 |
| 1125F |
|
272 |
161 |
$0.00 |
| 1111F |
|
205 |
109 |
$0.00 |
| 73090 |
|
13 |
12 |
$0.00 |
| 83615 |
|
32 |
25 |
$0.00 |
| 3017F |
|
35 |
28 |
$0.00 |
| 87340 |
|
17 |
14 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
31 |
26 |
$0.00 |
| 1123F |
|
17 |
12 |
$0.00 |